SE9501991L - Preparat för diagnostisering av det metabola syndromet och i detta ingående sjukdomstillstånd - Google Patents

Preparat för diagnostisering av det metabola syndromet och i detta ingående sjukdomstillstånd

Info

Publication number
SE9501991L
SE9501991L SE9501991A SE9501991A SE9501991L SE 9501991 L SE9501991 L SE 9501991L SE 9501991 A SE9501991 A SE 9501991A SE 9501991 A SE9501991 A SE 9501991A SE 9501991 L SE9501991 L SE 9501991L
Authority
SE
Sweden
Prior art keywords
metabolic syndrome
diagnosis
preparations
disease state
cortisol
Prior art date
Application number
SE9501991A
Other languages
Unknown language ( )
English (en)
Other versions
SE505391C2 (sv
SE9501991D0 (sv
Inventor
Per Maarin
Original Assignee
Medic Optimal Konsult Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medic Optimal Konsult Ab filed Critical Medic Optimal Konsult Ab
Priority to SE9501991A priority Critical patent/SE505391C2/sv
Publication of SE9501991D0 publication Critical patent/SE9501991D0/sv
Priority to CN96194229A priority patent/CN1078479C/zh
Priority to DE69626982T priority patent/DE69626982T2/de
Priority to ES96916423T priority patent/ES2189872T3/es
Priority to AT96916423T priority patent/ATE235258T1/de
Priority to BR9608683-1A priority patent/BR9608683A/pt
Priority to CA002222215A priority patent/CA2222215A1/en
Priority to PCT/SE1996/000708 priority patent/WO1996038179A1/en
Priority to DK96916423T priority patent/DK0835138T3/da
Priority to US08/952,638 priority patent/US6410339B1/en
Priority to RU97121292/14A priority patent/RU2171471C2/ru
Priority to AU59173/96A priority patent/AU716671B2/en
Priority to JP8536000A priority patent/JPH11505850A/ja
Priority to PT96916423T priority patent/PT835138E/pt
Priority to EP96916423A priority patent/EP0835138B1/en
Publication of SE9501991L publication Critical patent/SE9501991L/sv
Publication of SE505391C2 publication Critical patent/SE505391C2/sv
Priority to NO19975492A priority patent/NO319829B1/no
Priority to MXPA/A/1997/009234A priority patent/MXPA97009234A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Combined Controls Of Internal Combustion Engines (AREA)
SE9501991A 1995-05-30 1995-05-30 Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet SE505391C2 (sv)

Priority Applications (17)

Application Number Priority Date Filing Date Title
SE9501991A SE505391C2 (sv) 1995-05-30 1995-05-30 Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet
EP96916423A EP0835138B1 (en) 1995-05-30 1996-05-30 Preparation for diagnostic of the metabolic syndrome and diseases including the syndrome
DK96916423T DK0835138T3 (da) 1995-05-30 1996-05-30 Præparat til diagnosticering af metabolisk syndrom og sygdomme relateret til dette syndrom
RU97121292/14A RU2171471C2 (ru) 1995-05-30 1996-05-30 Способ диагностики метаболического синдрома и заболеваний, включающих в себя данный синдром
ES96916423T ES2189872T3 (es) 1995-05-30 1996-05-30 Sistema de diagnostico del sindrome metabolico y enfermedades que presentan el sindrome.
AT96916423T ATE235258T1 (de) 1995-05-30 1996-05-30 Zubereitung zur diagnostik des stoffwechselsyndroms und der dieses syndrom zeigende krankheiten
BR9608683-1A BR9608683A (pt) 1995-05-30 1996-05-30 Preparação para diagnóstico de síndrome metabólica e doenças incluindo a síndrome
CA002222215A CA2222215A1 (en) 1995-05-30 1996-05-30 Preparation for diagnostic of the metabolic syndrome and diseases including the syndrome
PCT/SE1996/000708 WO1996038179A1 (en) 1995-05-30 1996-05-30 Preparation for diagnostic of the metabolic syndrome and diseases including the syndrome
CN96194229A CN1078479C (zh) 1995-05-30 1996-05-30 诊断代谢综合症和包括该综合症疾病的试剂
US08/952,638 US6410339B1 (en) 1995-05-30 1996-05-30 Preparation for diagnosis of the metabolic syndrome and diseases including the syndrome
DE69626982T DE69626982T2 (de) 1995-05-30 1996-05-30 Zubereitung zur diagnostik des stoffwechselsyndroms und der dieses syndrom zeigende krankheiten
AU59173/96A AU716671B2 (en) 1995-05-30 1996-05-30 Preparation for diagnostic of the metabolic syndrome and diseases including the syndrome
JP8536000A JPH11505850A (ja) 1995-05-30 1996-05-30 代謝症候群および該症候群を含む病気の診断のための製剤
PT96916423T PT835138E (pt) 1995-05-30 1996-05-30 Preparacao para diagonostico da sindroma metabolica e doencas que incluem a sindroma
MXPA/A/1997/009234A MXPA97009234A (en) 1995-05-30 1997-11-28 Preparation for the diagnosis of the metabolic syndrome and diseases that include the sindr
NO19975492A NO319829B1 (no) 1995-05-30 1997-11-28 Preparat for diagnostisering av metabolsk syndrom samt sykdommer som omfatter syndromet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9501991A SE505391C2 (sv) 1995-05-30 1995-05-30 Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet

Publications (3)

Publication Number Publication Date
SE9501991D0 SE9501991D0 (sv) 1995-05-30
SE9501991L true SE9501991L (sv) 1996-12-01
SE505391C2 SE505391C2 (sv) 1997-08-18

Family

ID=20398470

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9501991A SE505391C2 (sv) 1995-05-30 1995-05-30 Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet

Country Status (16)

Country Link
US (1) US6410339B1 (sv)
EP (1) EP0835138B1 (sv)
JP (1) JPH11505850A (sv)
CN (1) CN1078479C (sv)
AT (1) ATE235258T1 (sv)
AU (1) AU716671B2 (sv)
BR (1) BR9608683A (sv)
CA (1) CA2222215A1 (sv)
DE (1) DE69626982T2 (sv)
DK (1) DK0835138T3 (sv)
ES (1) ES2189872T3 (sv)
NO (1) NO319829B1 (sv)
PT (1) PT835138E (sv)
RU (1) RU2171471C2 (sv)
SE (1) SE505391C2 (sv)
WO (1) WO1996038179A1 (sv)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217505B2 (en) * 1998-02-26 2007-05-15 Cortendo Ab Method for determining whether condition is symptom of metabolic syndrome
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
US20090117660A1 (en) * 2005-04-30 2009-05-07 Oakville Hong Kong Co., Limited Devices and methods for sample collection and analysis
CA2665164A1 (en) * 2006-10-06 2008-05-15 Nestec S.A. Compositions and multiplex assays for measuring biological mediators of physiological health
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
RU2444298C1 (ru) * 2010-07-15 2012-03-10 Учреждение Российской академии медицинских наук Научный центр клинической и экспериментальной медицины Сибирского отделения РАМН (НЦКЭМ СО РАМН) Способ диагностики метаболического синдрома
CN105973881A (zh) * 2016-04-27 2016-09-28 樊福好 一种检测机体活度的溶液及检测方法

Also Published As

Publication number Publication date
BR9608683A (pt) 1999-12-07
CA2222215A1 (en) 1996-12-05
ATE235258T1 (de) 2003-04-15
CN1078479C (zh) 2002-01-30
AU716671B2 (en) 2000-03-02
PT835138E (pt) 2003-08-29
CN1185743A (zh) 1998-06-24
WO1996038179A1 (en) 1996-12-05
EP0835138A1 (en) 1998-04-15
SE505391C2 (sv) 1997-08-18
DE69626982T2 (de) 2004-03-04
MX9709234A (es) 1998-10-31
RU2171471C2 (ru) 2001-07-27
DE69626982D1 (de) 2003-04-30
EP0835138B1 (en) 2003-03-26
NO975492D0 (no) 1997-11-28
SE9501991D0 (sv) 1995-05-30
JPH11505850A (ja) 1999-05-25
DK0835138T3 (da) 2003-07-21
AU5917396A (en) 1996-12-18
NO975492L (no) 1998-01-27
NO319829B1 (no) 2005-09-19
ES2189872T3 (es) 2003-07-16
US6410339B1 (en) 2002-06-25

Similar Documents

Publication Publication Date Title
SE9501991L (sv) Preparat för diagnostisering av det metabola syndromet och i detta ingående sjukdomstillstånd
Chiou et al. Andrographolide suppresses the expression of inducible nitric oxide synthase in macrophage and restores the vasoconstriction in rat aorta treated with lipopolysaccharide
Corman et al. Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy
Yokoe et al. Intermittent hypoxia reverses the diurnal glucose rhythm and causes pancreatic β‐cell replication in mice
Nakao et al. Effects of anesthesia on functional activation of cerebral blood flow and metabolism
Kalra Circumventing leptin resistance for weight control
Majka et al. Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization
Kassan et al. Clinical manifestations and early diagnosis of Sjögren syndrome
Natarajan et al. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes
Phillips et al. Alterations of protein turnover underlying disuse atrophy in human skeletal muscle
Borchers et al. Monocyte inflammation augments acrolein-induced Muc5ac expression in mouse lung
Lai et al. Mediators of inflammation and fibrosis
Ronis et al. Cytokine and chemokine expression associated with steatohepatitis and hepatocyte proliferation in rats fed ethanol via total enteral nutrition
RU97121292A (ru) Препарат для диагностики метаболического синдрома и заболеваний, включающих в себя данный синдром
WO2005117937A3 (en) Alpha-1- acid glycoprotein for the treatment of diabetes
Banasik et al. Low-calorie diet induced weight loss may alter regulatory hormones and contribute to rebound visceral adiposity in obese persons with a family history of type-2 diabetes
van der Mast et al. In vitro evaluation of an intravenous microdialysis catheter for therapeutic drug monitoring of gentamicin and vancomycin
Ousta et al. Microglial activation and neurological outcomes in a murine model of cardiac arrest
Armbrust et al. Early gene expression of hepatocyte growth factor in mononuclear phagocytes of rat liver after administration of carbon tetrachloride
Huh et al. Glucose-based peritoneal dialysis solution suppresses adiponectin synthesis through oxidative stress in an experimental model of peritoneal dialysis
Arencibia-Albite et al. Cocaine sensitization increases subthreshold activity in dopamine neurons from the ventral tegmental area
Lee et al. Components of metabolic syndrome and 5‐year change in insulin clearance–the Insulin Resistance Atherosclerosis Study
Muchnik et al. Effect of emotional stress on hearing
Spaziano et al. Nociceptin reduces the inflammatory immune microenvironment in a conventional murine model of airway hyperresponsiveness
Harrihar A et al. Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient

Legal Events

Date Code Title Description
NUG Patent has lapsed